Navigation Links
BMP Sunstone's Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
Date:2/27/2008

-- Recognition Substantiates Marketability of Propess(R) --

PLYMOUTH MEETING, PA., Feb. 27 (Xinhua-PRNewswire) -- BMP Sunstone Corporation (Nasdaq: BJGP) (''BMP Sunstone'' or the ''Company''), today announced that Propess(R) was recommended by the Obstetrics Group at the Obstetrics and Gynecology Branch of the Chinese Medical Association as the first line treatment for labor induction in late-stage pregnancy.

The Guidelines for Labor Induction in Late-Stage Pregnancy was published in the Chinese Journal of Obstetrics and Gynecology in January 2008. The Guidelines recommended Propess(R) as the first choice for cervical ripening, and further provided details on treatment dosage and agent-delivery.

David Gao, Chief Executive Officer of BMP Sunstone, stated, ''The recommendation of Propess(R) by the Chinese Medical Association further validates our research that Propess(R) is a leading product which should be effectively marketed to China's healthcare community. With over 421 Chinese hospitals now selling Propess(R), we have received positive feedback from doctors and will continue to educate healthcare providers about this product. Today's announcement certainly helps our cause."

BMP Sunstone started sales and marketing efforts of Propess(R) in China in 2005, after licensing the drug from its manufacturer, Cytokine PharmaSciences, Inc. (''Cytokine''). Known as Cervidil(R) in the US, Canada, Australia and New Zealand, Propess(R) is a sustained-release formulation of dinoprostone, a synthetic prostaglandin E2 used for cervical ripening in labor induction. Propess(R) is approved for use in over 50 countries around the world.

Denny Willson, President and CEO of Cytokine, stated, ''The Chinese Medical Association's recommendation that Propess(R) be the go-to product for cervical ripening strengthens our ability to educate and ultimately provide care in China. We are so pleased to work with BMP Sunstone to offer this leading product in China and we believe the demand for Propess(R) will continue to increase.''

About Cytokine PharmaSciences, Inc.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company developed and manufactures Cervidil(R)/Propess(R), used in the obstetrics field for cervical ripening in the induction of labor. Cytokine PharmaSciences is focused on the use of polymers for the delivery of drugs to the vagina or buccal cavity, as well as the development of novel targets and therapeutic agents for the treatment of inflammation, autoimmune diseases and cancer. For more information, visit to http://www.cytokinepharmasciences.com .

About BMP Sunstone Corporation

BMP Sunstone Corporation, through its subsidiaries, is a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The Company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio primarily focuses on the therapeutic areas of women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Pennsylvania.

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including educating healthcare providers and the future demand for Propess(R). These statements are subject to uncertainties and risks including, but not limited to, the ability to meet with healthcare providers and impact the acceptance of the product in the marketplace and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

BMP Sunstone Corporation:

Fred M. Powell

Chief Financial Officer

Tel: 610-940-1675

Integrated Corporate Relations, Inc.

In the U.S.:

Ashley Ammon MacFarlane and Christine Duan

Tel: 203-682-8200

In Asia:

Xuyang Zhang

Tel: +86-10-8523-3087


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
2. Hepatitis C Testing Recommended for Anyone with a Tattoo
3. Most With High Blood Pressure Dont Follow Recommended Diet
4. First biomarker discovered that predicts prostate cancer outcome
5. FDA Approves First Anti-Psychotic for Kids
6. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
7. First study examines newly-licensed RN work attitudes and intentions
8. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
11. High and mighty: first common height gene identified by researchers behind obesity gene finding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
(Date:5/26/2016)... ... May 26, 2016 , ... In an effort to provide hair restoration information to the ... users and those who do not use the app. Dr. Mohebi, the founder of Parsa ... Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to the Snapchat ...
(Date:5/26/2016)... ... 26, 2016 , ... Eating Recovery Center, Washington ... a brand new child and adolescent residential treatment center on June 1. The ... more specialized eating disorder treatment and access to life-saving care. , To celebrate, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/26/2016)... , May 26, 2016 Since ... matured into an essential life science tool for conducting ... applications. BCC Research reveals in its new report that ... growth phase, one powered by a range of new ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
Breaking Medicine Technology: